Adjunctive Treatment with Acetyl-L-carnitine for Cognitive and Negative Symptoms in Schizophrenia: A Randomized Controlled Trial

Adjunctive Treatment with Acetyl-L-carnitine for Cognitive and Negative Symptoms in Schizophrenia: A RCT - prospective trail

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087479

Enrollment

Registered

2025-05-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F20-F29- Schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders

Interventions

Intervention1: Acetyl L-Carnitine (ALC) in ameliorating the negative and cognitive symptomatology associated with schizophrenia: Acetyl L-Carnitine (ALC) in ameliorating the negative and cognitive sym

Eligibility

Inclusion criteria

Inclusion criteria: Drug-na ve patients Aged between 18 and 45 years Meeting DSM-5 diagnostic criteria for schizophrenia

Exclusion criteria

Exclusion criteria: Refusal to provide informed consent Presence of comorbid major psychiatric disorders

Design outcomes

Primary

Measure	Time frame
the potential of Acetyl-L-Carnitine (ALC) as an adjunctive treatment to Olanzapine in reducing negative symptoms and cognitive deficits in patients with schizophrenia.Timepoint: the potential of Acetyl-L-Carnitine (ALC) as an adjunctive treatment to Olanzapine in reducing negative symptoms and cognitive deficits in patients with schizophrenia.	—

Secondary

Measure	Time frame
Adjunctive treatment with Acetyl-L-Carnitine (ALC) alongside Olanzapine will lead to a more significant reduction in negative and cognitive symptoms of schizophrenia compared to Olanzapine monotherapy alone, as measured by PANSS and MoCA scores over a 6-week period.Timepoint: 6weeks	—

Countries

India

Contacts

Public ContactShalmali Kulkarni

IMSandSUMHOSPITAL(SOADEEMEDUNIVERSITY)

jamunadas@soa.ac.in09437823251

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026